Which has stronger valuation and earnings, ALXO or ANVS?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.13 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is ALXO or ANVS more profitable?

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Annovis Bio N/A -685.98% -258.77%

Does the media favor ALXO or ANVS?

In the previous week, ALX Oncology had 3 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for ALX Oncology and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat ALX Oncology's score of 0.73 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ANVS or ADAG?

Adagene has higher revenue and earnings than Annovis Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A Adagene $7.67M 24.46 -$17.61M N/A N/A

Is ANVS or ADAG more profitable?

Adagene's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% Adagene N/A N/A N/A

Does the media refer more to ANVS or ADAG?

In the previous week, Annovis Bio and Annovis Bio both had 2 articles in the media. Annovis Bio's average media sentiment score of 1.11 beat Adagene's score of 0.73 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NKTX or ANVS?

Nkarta is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is NKTX or ANVS more profitable?

Nkarta's return on equity of -39.64% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Annovis Bio N/A -685.98% -258.77%

Does the media refer more to NKTX or ANVS?

In the previous week, Nkarta had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat Nkarta's score of 0.55 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANVS or CHRS?

In the previous week, Annovis Bio had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Coherus Oncology. Annovis Bio's average media sentiment score of 1.11 beat Coherus Oncology's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, IPHA or ANVS?

Annovis Bio has lower revenue, but higher earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 17.65 -$55.64M N/A N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is IPHA or ANVS more profitable?

Innate Pharma's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Annovis Bio N/A -685.98% -258.77%

Does the media refer more to IPHA or ANVS?

In the previous week, Innate Pharma and Innate Pharma both had 2 articles in the media. Annovis Bio's average media sentiment score of 1.11 beat Innate Pharma's score of 0.40 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annovis Bio (ANVS) Competitors

$1.18 +0.02 (+1.28%)

Closing price 03:59 PM Eastern

Extended Trading

$1.16 -0.03 (-2.45%)

As of 06:54 PM Eastern

Compare

ANVS vs. ALXO, ADAG, NKTX, CHRS, and IPHA

Should you buy Annovis Bio stock or one of its competitors? Annovis Bio's main competitors and comparable companies include ALX Oncology (ALXO), Adagene (ADAG), Nkarta (NKTX), Coherus Oncology (CHRS), and Innate Pharma (IPHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annovis Bio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Annovis Bio	N/A	-685.98%	-258.77%

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 15.9% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

ALX Oncology has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

In the previous week, ALX Oncology had 3 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for ALX Oncology and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat ALX Oncology's score of 0.73 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology currently has a consensus target price of $4.60, suggesting a potential upside of 269.48%. Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 930.04%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

ALX Oncology beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Adagene?

Annovis Bio (NYSE:ANVS) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Annovis Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Adagene has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Adagene has higher revenue and earnings than Annovis Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Adagene	$7.67M	24.46	-$17.61M	N/A	N/A

In the previous week, Annovis Bio and Annovis Bio both had 2 articles in the media. Annovis Bio's average media sentiment score of 1.11 beat Adagene's score of 0.73 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio currently has a consensus target price of $12.00, indicating a potential upside of 930.04%. Adagene has a consensus target price of $8.67, indicating a potential upside of 205.16%. Given Annovis Bio's higher probable upside, equities research analysts clearly believe Annovis Bio is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 15.9% of Annovis Bio shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Adagene's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Adagene	N/A	N/A	N/A

Summary

Adagene beats Annovis Bio on 8 of the 12 factors compared between the two stocks.

How does Annovis Bio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Nkarta's return on equity of -39.64% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Annovis Bio	N/A	-685.98%	-258.77%

Nkarta currently has a consensus target price of $11.20, indicating a potential upside of 341.81%. Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 930.04%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 15.9% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nkarta had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Nkarta and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat Nkarta's score of 0.55 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Summary

Nkarta beats Annovis Bio on 8 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Coherus Oncology?

Annovis Bio (NYSE:ANVS) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Coherus Oncology has higher revenue and earnings than Annovis Bio. Coherus Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Coherus Oncology	$42.17M	4.30	$168.02M	-$1.03	N/A

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Annovis Bio had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Coherus Oncology. Annovis Bio's average media sentiment score of 1.11 beat Coherus Oncology's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio currently has a consensus target price of $12.00, indicating a potential upside of 930.04%. Coherus Oncology has a consensus target price of $11.00, indicating a potential upside of 836.17%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Annovis Bio has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Coherus Oncology's return on equity of -222.75% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Annovis Bio has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

Annovis Bio and Coherus Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Innate Pharma presently has a consensus target price of $6.67, indicating a potential upside of 314.08%. Annovis Bio has a consensus target price of $12.00, indicating a potential upside of 930.04%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Innate Pharma's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Annovis Bio	N/A	-685.98%	-258.77%

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 15.9% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Annovis Bio has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	17.65	-$55.64M	N/A	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Innate Pharma has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

In the previous week, Innate Pharma and Innate Pharma both had 2 articles in the media. Annovis Bio's average media sentiment score of 1.11 beat Innate Pharma's score of 0.40 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innate Pharma beats Annovis Bio on 6 of the 11 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$50.58M	$3.84B	$7.10B	$22.70B
Dividend Yield	N/A	3.64%	2.53%	3.74%
P/E Ratio	-0.66	12.99	274.61	27.77
Price / Sales	N/A	1,288.54	601.02	20.15
Price / Cash	N/A	121.76	77.38	39.56
Price / Book	1.85	16.63	10.92	4.64
Net Income	-$28.85M	-$22.67M	$3.50B	$1.08B
7 Day Performance	-9.89%	-3.06%	-2.11%	-1.07%
1 Month Performance	-30.50%	-10.76%	-6.34%	-5.03%
1 Year Performance	-46.62%	21.10%	8.81%	5.78%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	2.8928 of 5 stars	$1.19 +1.3%	$12.00 +912.7%	-45.7%	$50.58M	N/A	N/A	7	Gap Up
ALXO ALX Oncology	3.1144 of 5 stars	$1.64 -1.5%	$4.60 +181.3%	-28.2%	$226.09M	N/A	N/A	48
ADAG Adagene	3.8172 of 5 stars	$3.24 +1.1%	$8.67 +167.2%	+46.5%	$214.07M	$7.67M	N/A	128	Gap Up
NKTX Nkarta	2.8525 of 5 stars	$2.96 +2.8%	$11.20 +278.3%	+20.2%	$210.92M	N/A	N/A	106
CHRS Coherus Oncology	1.5358 of 5 stars	$1.34 -2.6%	$11.00 +724.0%	-28.4%	$206.26M	$42.17M	N/A	144

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, ADAG, NKTX, CHRS, and IPHA

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Adagene?

Summary

How does Annovis Bio compare to Nkarta?

Summary

How does Annovis Bio compare to Coherus Oncology?

Summary

How does Annovis Bio compare to Innate Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, ADAG, NKTX, CHRS, and IPHA

How does Annovis Bio compare to ALX Oncology?

Is ALXO or ANVS more profitable?

Do insiders & institutionals hold more shares of ALXO or ANVS?

Which has stronger valuation and earnings, ALXO or ANVS?

Which has more risk & volatility, ALXO or ANVS?

Does the media favor ALXO or ANVS?

Do analysts prefer ALXO or ANVS?

Summary

How does Annovis Bio compare to Adagene?

Which has more risk and volatility, ANVS or ADAG?

Which has stronger earnings & valuation, ANVS or ADAG?

Does the media refer more to ANVS or ADAG?

Do analysts prefer ANVS or ADAG?

Do insiders and institutionals believe in ANVS or ADAG?

Is ANVS or ADAG more profitable?

Summary

How does Annovis Bio compare to Nkarta?

Is NKTX or ANVS more profitable?

Do analysts prefer NKTX or ANVS?

Do insiders & institutionals believe in NKTX or ANVS?

Does the media refer more to NKTX or ANVS?

Which has stronger valuation and earnings, NKTX or ANVS?

Which has more risk and volatility, NKTX or ANVS?

Summary

How does Annovis Bio compare to Coherus Oncology?

Which has higher valuation & earnings, ANVS or CHRS?

Do insiders & institutionals believe in ANVS or CHRS?

Does the media prefer ANVS or CHRS?

Do analysts rate ANVS or CHRS?

Is ANVS or CHRS more profitable?

Which has more volatility & risk, ANVS or CHRS?

Summary

How does Annovis Bio compare to Innate Pharma?

Do analysts prefer IPHA or ANVS?

Is IPHA or ANVS more profitable?

Do institutionals and insiders believe in IPHA or ANVS?

Which has preferable valuation and earnings, IPHA or ANVS?

Which has more volatility and risk, IPHA or ANVS?

Does the media refer more to IPHA or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools